A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Urovant Sciences GmbH
- Target Recruit Count
- 85
- Registration Number
- NCT05491525
- Locations
- 🇺🇸
Albany Medical College, Albany, New York, United States
🇺🇸Childrens Hospital New Orleans, New Orleans, Louisiana, United States
🇺🇸Wichita Urology Group, Wichita, Kansas, United States
Composur: Study to Understand the Performance of Vibegron in Participants With Overactive Bladder (OAB)
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Urovant Sciences GmbH
- Target Recruit Count
- 400
- Registration Number
- NCT05067478
- Locations
- 🇺🇸
Southern Urogynecology, West Columbia, South Carolina, United States
🇺🇸Associated Urologists of North Carolina, Raleigh, North Carolina, United States
🇺🇸Medicus Alliance Clinical Research Organization Inc., Sugar Land, Texas, United States
URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence
- Conditions
- Interventions
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- Urovant Sciences GmbH
- Target Recruit Count
- 80
- Registration Number
- NCT04211831
- Locations
- 🇺🇸
University of Southern California - Norris Hospital, Los Angeles, California, United States
🇺🇸Orange County Urology Associates, Laguna Hills, California, United States
🇺🇸Institute For Female Pelvic Medicine, Allentown, Pennsylvania, United States
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
- First Posted Date
- 2019-09-25
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Urovant Sciences GmbH
- Target Recruit Count
- 276
- Registration Number
- NCT04103450
- Locations
- 🇺🇸
Clinical Research of Central Florida, Winter Haven, Florida, United States
🇺🇸American Institute of Research, Los Angeles, California, United States
🇺🇸Quantum Clinical Trials, Miami, Florida, United States
Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
- First Posted Date
- 2019-04-03
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Urovant Sciences GmbH
- Target Recruit Count
- 1105
- Registration Number
- NCT03902080
- Locations
- 🇺🇸
Boston Clinical Trials Inc - Urology, Boston, Massachusetts, United States
🇺🇸Advances In Health, Inc., Houston, Texas, United States
🇺🇸Excel Clinical Research - Internal Medicine, Las Vegas, Nevada, United States
Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome
- First Posted Date
- 2019-01-16
- Last Posted Date
- 2021-08-02
- Lead Sponsor
- Urovant Sciences GmbH
- Target Recruit Count
- 222
- Registration Number
- NCT03806127
- Locations
- 🇺🇸
Mandeville Private Physician Group, LLC, Mandeville, Louisiana, United States
🇺🇸Medical Research Center of Connecticut LLC, Hamden, Connecticut, United States
🇺🇸Synexus Clinical Research US, Inc. - Desert Clinical Research, LLC, Mesa, Arizona, United States
An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).
- Conditions
- Interventions
- First Posted Date
- 2018-07-11
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- Urovant Sciences GmbH
- Target Recruit Count
- 506
- Registration Number
- NCT03583372
- Locations
- 🇺🇸
Coastal Clinical Research Inc., Mobile, Alabama, United States
🇺🇸Downtown L.A. Research Center Inc., Los Angeles, California, United States
🇺🇸Women's Clinic of Lincoln PC, Lincoln, Nebraska, United States
A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)
- Conditions
- Interventions
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2021-03-04
- Lead Sponsor
- Urovant Sciences GmbH
- Target Recruit Count
- 1530
- Registration Number
- NCT03492281
- Locations
- 🇺🇸
Prime-Care Clinical Research, Laguna Hills, California, United States
🇺🇸KO Clinical Research, Fort Lauderdale, Florida, United States
🇺🇸Vital Pharm Research Inc., Hialeah, Florida, United States
Phase 2A Clinical Trial Evaluating the Potential Activity and Safety of hMaxi-K Gene for ED
- Conditions
- Interventions
- First Posted Date
- 2016-03-21
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- Urovant Sciences GmbH
- Target Recruit Count
- 26
- Registration Number
- NCT02713789
- Locations
- 🇰🇼
Dasman Diabetes Institute, Kuwait city, Dasman, Kuwait
Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer
- Conditions
- Interventions
- First Posted Date
- 2013-06-05
- Last Posted Date
- 2019-05-08
- Lead Sponsor
- Urovant Sciences GmbH
- Target Recruit Count
- 13
- Registration Number
- NCT01870037
- Locations
- 🇺🇸
AccuMed Research Associates, Garden City, New York, United States
🇺🇸NYU, New York, New York, United States
🇺🇸Premier Medical Group of the Hudson Valley, PC, Poughkeepsie, New York, United States